Table 2 HBV, HCV and HDV infection in HCC patients and controls and estimates of HCC risk
From: A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa
Hepatitis markers | Controls | HCC cases | Unadjusted HCC risk | Adjusted HCC risks | ||||
|---|---|---|---|---|---|---|---|---|
| Â | No | % | No | % | OR | (95Â % CI) | OR | (95Â % CI) |
HBV status | ||||||||
 HBsAg positive | 9 | 10.6 | 58 | 65.9 | 16.3 | 7.2-37.1 | 141.7 | 11.5-1747.6 |
 HBeAg positive | 1 | 11.1 | 5 | 8.6 | 11.2 | 0.6-207.3 | 38.79 | 4.04-305.2 |
 Anti-HBc positive | 67 | 78.8 | 73 | 82.9 | 1.31 | 0.6-28 | 0.68 | 0.03-16.7 |
 Anti-HBs positive | 59 | 69.4 | 23 | 26.1 | 0.16 | 0.8-3.2 | 0.56 | 0.018-15.1 |
HCV status | ||||||||
 Anti-HCV positive | 3 | 3.5 | 23 | 26.1 | 9.7 | 2.7-33.6 | 51.9 | 3.8-711.03 |
HDV status | ||||||||
 Anti-HDV positive HBV-related | 1 | 11.1 | 24 | 41.1 | 5.72 | 0.75-39.27. | 5.65 | 0.66-48.16 |
 Anti-HDV positive | 1 | 1.17 | 24 | 27.27 | 29.3 | 4.1-1231 | 35.65 | 3.66-682.16 |